Metformin as an adjuvant option for systemic treatment of breast cancer

Metformin as an adjuvant option for systemic treatment of breast cancer

The modification of the used and development of new treatment regimens significantly improved the overall, recurrence-free survival and quality of life of patients with malignant oncological diseases. Recently, drugs used in non-oncological pathology have been introduced into cancer treatment regime...

Full description

Bibliographic Details
Main Authors:	D.I. Avierin, V.F. Zavizion
Format:	Article
Language:	English
Published:	Dnipro State Medical University 2023-12-01
Series:	Medičnì Perspektivi
Subjects:	breast cancer metformin chemotherapy modification neoadjuvant treatment luminal type medical resistance survive of patient
Online Access:	https://journals.uran.ua/index.php/2307-0404/article/view/294154

Similar Items

RecurIndex assay as an aid for adjuvant chemotherapy decisions in HR-positive HER2-negative breast cancer patients
by: Haibo Wang, et al.
Published: (2022-12-01)

Efficacy of Metformin as Adjuvant Therapy in Metastatic Breast Cancer Treatment
by: Nourhan M. Essa, et al.
Published: (2022-09-01)

Metformin in neoadjuvant systemic therapy of breast cancer patients with metabolic syndrome
by: Liubota Roman, et al.
Published: (2018-01-01)

Association of <i>SLC12A1</i> and GLUR4 Ion Transporters with Neoadjuvant Chemoresistance in Luminal Locally Advanced Breast Cancer
by: Montserrat Justo-Garrido, et al.
Published: (2023-11-01)

Circulating microRNAs as indicators in the prediction of neoadjuvant chemotherapy response in luminal B breast cancer
by: Zhuo Zhang, et al.
Published: (2021-12-01)

Neoadjuvant Metformin Added to Systemic Therapy Increases Pathological Complete Response in Breast Cancer: A Cross-sectional Study, Mexico Hospital, Costa Rica
by: Alicia Van der Laat, et al.
Published: (2018-03-01)

Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting
by: Antonino Grassadonia, et al.
Published: (2021-07-01)

Neoadjuvant Chemoradiotherapy versus Chemotherapy for Gastroesophageal Junction Adenocarcinoma; Which Is the Optimal Treatment Option?
by: Eric Zandirad, et al.
Published: (2022-11-01)

Estrogen Receptor and Claudin-6 Might Play Vital Roles for Long-Term Prognosis in Patients With Luminal A Breast Cancer Who Underwent Neoadjuvant Chemotherapy
by: Yushi Liu, et al.
Published: (2022-06-01)

Neoadjuvant chemotherapy for breast cancer: Pathologic response rates but not tumor size, has an independent prognostic impact on survival
by: Gilles Houvenaeghel, et al.
Published: (2024-02-01)

Predictive Factors of Long-Term Survival after Neoadjuvant Radiotherapy and Chemotherapy in High-Risk Breast Cancer
by: Jan Haussmann, et al.
Published: (2022-08-01)

The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin
by: Elisabet Cuyàs, et al.
Published: (2019-03-01)

New Advances in the Research of Resistance to Neoadjuvant Chemotherapy in Breast Cancer
by: Junsha An, et al.
Published: (2021-09-01)

Survival outcomes of neoadjuvant versus adjuvant chemotherapy in triple-negative breast cancer: a meta-analysis of 36,480 cases
by: Lin-Yu Xia, et al.
Published: (2020-06-01)

Role of metformin in radiotherapy and chemotherapy
by: Yasemin Benderli Cihan
Published: (2019-03-01)

Development and validation of an ultrasound-based radiomics nomogram for predicting the luminal from non-luminal type in patients with breast carcinoma
by: Jiangfeng Wu, et al.
Published: (2022-11-01)

Metformin as a Potential Treatment Option for Endometriosis
by: Żaneta Kimber-Trojnar, et al.
Published: (2022-01-01)

Effect of the Surgery Type, Mastectomy vs. Breast Conserving Surgery, on Outcomes of Patients With Locally Advanced Breast Cancer Receiving Neoadjuvant Therapy
by: Negar Mashoori, et al.
Published: (2017-12-01)

DNA methylation changes in response to neoadjuvant chemotherapy are associated with breast cancer survival
by: Christine Aaserød Pedersen, et al.
Published: (2022-06-01)

Metformin as a new option in the medical management of breast fibroadenoma; a randomized clinical trial
by: Sadaf Alipour, et al.
Published: (2021-08-01)

The impact of age group in breast cancer survival outcome according to neoadjuvant treatment response: A matched case–control study
by: Chung‐Liang Li, et al.
Published: (2022-03-01)

Neoadjuvant chemotherapy for primary sarcoma of the breast: a case report
by: Chieko Miyazaki, et al.
Published: (2019-09-01)

Study of Tumour Cellularity in Locally Advanced Breast Carcinoma on Neo-Adjuvant Chemotherapy
by: Swarup Kumar, et al.
Published: (2014-04-01)

The choice of a neoadjuvant chemotherapy cycle for breast cancer has significance in clinical practice: results from a population-based, real world study
by: Litong Yao, et al.
Published: (2022-05-01)

Comparison of responses to neoadjuvant and adjuvant chemotherapies in muscle-invasive bladder cancer
by: Serhat Sekmek, et al.
Published: (2023-11-01)

Treatment times in breast cancer patients receiving neoadjuvant vs adjuvant chemotherapy: Is efficiency a benefit of preoperative chemotherapy?
by: Nicole M. Melchior, et al.
Published: (2020-04-01)

Colour Coding Navigation: “Triage” Techniques to Improve Compliance in Breast Cancer Patients Requiring Primary Chemotherapy
by: Carol Ann Benn, et al.
Published: (2020-10-01)

The main markers of the long-term efficiency of neoadjuvant chemotherapy in breast cancer (review of literature)
by: V F Semiglazov, et al.
Published: (2013-12-01)

Androgen Receptor Expression in Locally Advanced Breast Cancer Predicts Lack of Pathological Complete Response After Neoadjuvant Treatment
by: allan Ramos-Esquivel, et al.
Published: (2017-12-01)

Neoadjuvant and Adjuvant Chemotherapy in Osteosarcoma (The Experience of HORC in the Shariati Hospital)
by: Alimoghadam K, et al.
Published: (2004-07-01)

How Long is It Safe to Wait for Breast Surgery After Completion of Neoadjuvant Chemotherapy?
by: Ma T, et al.
Published: (2021-02-01)

Patients achieved pCR during neoadjuvant chemotherapy had better outcome than adjuvant chemotherapy setting in breast cancer: A comparative study
by: Jida Chen, et al.
Published: (2023-01-01)

The experience of preoperative treatment with anthracyclines in patients with luminal-type B locally advanced breast cancer
by: D. Ye. Cherniavskyi, et al.
Published: (2022-09-01)

Time to surgery and survival in breast cancer
by: Doyeon An, et al.
Published: (2022-11-01)

Perioperative chemotherapy versus adjuvant chemotherapy treatment for resectable locally advanced gastric cancer: a retrospective cohort study
by: Pengfei Su, et al.
Published: (2023-10-01)

Prognostic Nutritional Index (PNI) in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy as a Useful Prognostic Indicator
by: Li Chen, et al.
Published: (2021-03-01)

Response to neoadjuvant chemotherapy and survival of children and adolescents with high-grade osteosarcoma treated based on the EURAMOS-1 protocol
by: Amaranto Suárez-Mattos, et al.
Published: (2022-01-01)

Surgical options of the breast and clinical outcomes of breast cancer patients after neoadjuvant chemotherapy: A single-center retrospective study
by: Yuting Sang, et al.
Published: (2022-10-01)

Conversion of immunohistochemical markers and breast density are associated with pathological response and prognosis in very young breast cancer patients who fail to achieve a pathological complete response after neoadjuvant chemotherapy
by: Zhao Y, et al.
Published: (2019-06-01)

Metformin Therapy and Breast Cancer Incidence in the Ha’il Region
by: Mhdia Osman, et al.
Published: (2023-01-01)